PDF
Citation
Print
INTRODUCTION
Juvenile nasopharyngeal angiofibroma (JNA) is a rare, highly vascularized tumor that presents predominantly in males during the second decade of life. Typically located in the superior nasal cavity, the tumor often invades into the base of the skull and adjacent structures. Based on its histological features, JNA is commonly described as a neoplasm, but due to its hypervascularity and lack of a true capsule, surgeons often consider this tumor as more akin to a vascular malformation.1) Its complex network of arterial supply may arise from up to 10 potential branches of the external carotid artery (ECA) and internal carotid artery (ICA) circulation, including ECA-ICA anastomoses.2)16)19)
The ECA-ICA anastomoses directly involved in the vascular supply of this tumor may lead to inadvertent injection of embolic material into the ICA circulation by anterograde crossing from the ECA branches through the tumor feeders.3)5)7)11–13)18)20) Presence of these tumor feeders from ECA-ICA anastomoses has led operators to refrain from pursuing a more aggressive tumor embolization due to the risk of potential embolic strokes.21)
Here, we describe our experience in embolizing JNA tumors using a balloon-assisted embolization (BAE) technique in which a Hyperglide balloon in the C2-C4 ICA segments is simultaneously inflated during injection of Onyx into the tumor feeders. The goal of such technique is to avoid embolic complications that arise from shunting of the embolic material from the tumor feeders into the ICA circulation, thus providing a safe and effective approach for tumor embolization.
MATERIALS AND METHODS
We retrospectively reviewed 9 consecutive cases of JNA patients that underwent pre-operative intra-arterial tumor embolization followed by surgical resection between 2013–2018. All tumors displayed tumor feeders from ECA-ICA anastomoses, were embolized using Onyx-34, and were performed by a single neurointerventionist. Data recorded included age, sex, ethnicity, clinical presentation, Radkowski stage, tumor size, tumor arterial feeders, tumor volume embolization, extent of resection, average surgical blood loss (ASBL), transfusion details, surgical procedure time, and embolization-related and post-operative complications. The assessment of the Radkowski stage has been described previously.17) Tumor volume embolization was evaluated on 2-D digital subtraction angiography images by performing angiographic runs of the ECA at the start and at end of the embolization procedure. An independent blinded reader measured the tumor volume before (Pre-V) and after (Post-V) the procedure using the formula V=(A×B×C)/3, which has been previously described.14) The tumor volume embolization was the calculated as [Pre-V] − [Post-V]/Pre-V. Need for surgical reintervention was determined by recurrence of tumor or symptoms. This study was approved by the Institutional Review Board.
Embolization technique
Under general anesthesia, femoral access is gained on both sides using a 6-French (6F) sheath. After performing 2-D angiographic runs of the ECA and ICA bilaterally, a 6F Envoy DA guiding catheter is advanced and placed in the ICA ipsilateral to the tumor feeders. Heparinization is used to prevent thrombotic complications, maintaining an activated clotting time between 200–300 seconds. A 5×30 mm Hyperglide balloon (Medtronic, Minneapolis, MN, USA) with a microwire is then introduced through the guiding catheter and placed at the carotid siphon, extending through the ICA C2-C4 segments. A second 6F Envoy DA catheter (DePuy Synthes, Raynham, MA, USA) is then advanced and placed into the ipsilateral ECA. A dual lumen micro-balloon catheter, Scepter balloon (Terumo, Tokyo, Japan) loaded with Traxcess 014 microwire (Terumo, Tokyo, Japan), is then inserted into the tumor feeder of interest. 2-D angiographic runs are performed to confirm maximal distal positioning of the balloon microcatheter tip. The 5×30 mm Hyperglide in the ICA is inflated between 2–5 minutes to protect the ICA circulation during injection of the embolic material. The micro-balloon catheter injection lumen is then primed with Onyx-34 (Medtronic, Minneapolis, MN, USA), the Scepter balloon is inflated, and Onyx-34 is slowly infused using a blank roadmap visualization to achieve maximal distal penetration. The Scepter balloon is deflated and a 2-D angiography run is performed to evaluate the extent of tumor volume embolization. The Hyperglide balloon is then deflated to restore flow in the ICA circulation, followed by removal of the Scepter balloon in the ECA. This process is then repeated until tumor vascular contrast blush is no longer present or embolization of all tumor feeders from the ECA was achieved.
Following embolization of tumor feeders from the ECA, a 2-D angiographic run of the ICA is obtained to identify tumor feeders from the ICA. In such case, a Hyperglide balloon is inflated just distal to the arterial pedicle to insert a dual micro-balloon catheter into the tumor feeder of interest. Once the catheter is placed in the maximal distal segment the wire is removed, and the balloon is deflated and withdrawn slightly to ensure coverage of the feeder base in order to prevent liquid embolic material to reflux back to the ICA. The protective balloon is then inflated sealing the pedicle from the ICA to prevent reflux. Onyx-34 is slowly injected into the ICA feeder under complete balloon seal via blank roadmap technique allowing for safe and effective penetration of the embolic material. The microcatheter is removed, followed by balloon deflation. At the end of the procedure, injection of the ECA and ICA is performed to assess the percentage of tumor volume embolized. Please refer to Fig. 1 for an illustrative representation of this technique.
RESULTS
Among 9 patients included in this series, all were males and mean age was 14.1±6.3 years (range, 9–29 years). Epistaxis was the most common symptom at the initial presentation (89%) followed by nasal obstruction (56%), and a 44% of tumors were Radkowski stage 2b. All cases displayed tumor arterial supply from ECA and ICA circulations on 2-D catheter angiograms, with a total number of arterial tumor feeders embolized in a given session ranging between 2–6.
The mean tumor volume embolization was 84.4±12.4% (range, 60–100%), with subsequent gross total and subtotal resection achieved in 89% of the cases. A complete tumor volume embolization was achieved in Cases 7 and 8 and had a Radkowski stage 2a and 2b, respectively. Mean ASBL was 722 mL (range, 50–2,000 mL), and in the last 6 cases was 333 mL (range, 50–600 mL). Mean surgical procedure time was 282.6 mins (±85.4 mins). One case underwent a second embolization for tumor recurrence 14 months after the initial surgery (Case 5) and one case required a repeat embolization session to address residual tumor 4 years after the initial procedure (Case 6). One patient experienced late-onset, transient facial palsy as a surgical-related complication (Case 2).
DISCUSSION
JNA is a rare tumor usually presenting among young adolescent males. Although considered as a benign tumor, it has a locally aggressive behavior invading adjacent structures and eroding bone, thus carrying a significant morbidity during surgical resection.1) The tumor is composed by a complex matrix of blood vessels with a single endothelial lining surrounded by fibrous stroma, resulting in a highly fragile mass with a significant risk of massive bleeding with even minimal manipulation.
In JNA, tumor feeders tend to arise from the ECA by two of its branches: the internal maxillary artery and the ascending pharyngeal artery. However, upregulated expression of vascular growth factors induces tumor growth and consequentially blood supply from segments or branches of the ICA, from which ECA-ICA anastomoses often develop. Tumors feeders that exhibit shunting into the ICA circulation through these anastomoses are recommended to be embolized using the BAE technique to ensure the safety and efficacy of the procedure. Otherwise, inadvertent injection of these anastomoses may result in embolic complications with potential cranial nerve lesions and vision loss.5)7)9)11–13)15)18)20)
The complexity of the vascular supply of JNA coupled with its intraoperative-associated morbidity has led to the use of endovascular therapy to perform preoperative embolization, as first described in 1979.8) Preoperative tumor embolization using embolic agents (e.g., Onyx) has shown to decrease operative times and blood loss.10) At our institution, Onyx is the preferred embolic agent for tumor embolization, as it provides a deeper penetration to tumor capillaries, improved fluoroscopic visibility, and lower risk of catheter adherence and secondary vessel injury. However, one of most significant risk of any embolic material is inadvertent injection into the arterial system. Although the use of a percutaneous tumor puncture (i.e., direct tumor puncture)4) may allow for better visibility during injection of the embolic material, its benefit is outweighed by the potential migration of embolic material into ICA branches through ECA anastomoses.3)5)
This scenario represents a challenge to neurointerventionists, as the risk of embolizing an ICA branch through ECA-ICA anastomoses hinders a complete tumor embolization, leading to a significant risk of blood loss during surgical resection. Use of the BAE technique at our institution has allowed us to overcome these issues. Additionally, balloon protection of the ICA circulation while injecting embolic material through the ECA facilitates obliteration of tumor feeders that would have remained patent otherwise. In our series, there were no complications from inadvertent embolization of arterial vessels, embolic material entering the ICA circulation, or ophthalmic artery involvement.
We reported a high tumor volume embolization of 84% with over 90% of tumor volume embolization was achieved in four cases, contrary to other reports where successful tumor devascularization was only achieved with direct tumor puncture.3) Despite a prolonged procedure time when selectively embolizing tumor feeders as opposed to direct tumor puncture, the benefit from controlling the injection of the embolic material in our approach outweighs the potential risks of increasing the procedure time. In addition, direct tumor puncture has its own risks that cannot be disregarded. Of note, radiation dose and fluoroscopy time were within our institution’s standards. Furthermore, injection of Onyx with concurrent balloon protection of the ICA reduces procedure time when compared to the traditional trans-arterial approach, as fewer tumor feeders will need to be individually selected for embolization.
The use of simultaneous balloon occlusion across the ophthalmic and petrous segments of the ICA is crucial to safely embolize the tumor feeders, but is not without its own risks. There is a potential risk for vascular injury, such as perforation or iatrogenic dissection of the vessel which may lead to hemorrhagic or ischemic complications, respectively. A study analyzing risks for ischemic complications after a carotid sacrifice procedure with balloon occlusion revealed acute hemodynamic changes in blood pressure and heart rate when the balloon was inflated,6) as fluctuating hemodynamic parameters may pose a risk for hypoperfusion ischemia. Due to its potential risks, baseline blood pressure, the effects of the anesthetic agent on compensatory regulatory mechanisms, and occlusion time of ICA should all be considered during tumor embolization and simultaneous balloon occlusion (SBO). JNA patients, typically young males without pre-existing medical co-morbidities, are more likely to tolerate SBO through collateral flow through the anterior communicating artery or ipsilateral posterior communicating artery, if present. In our series, no patients in our cohort developed ischemia secondary to hypoperfusion from SBO.
In our series, use of the BAE technique resulted in low-risk blood loss during surgical resection as shown by the mean ASBL of 722 mL (range, 50–2,000 mL), lower than the intraoperative blood loss of 862 mL reported by Elhammady et al.9) in their case series of JNA tumors treated by transarterial embolization. Further, mean ASBL was reduced to 333 mL within one year, a reduction of 78%, and lower than reported in the literature. In severe cases, given the extent tumor invasion to bone structures, significant blood loss can be expected even if the tumor is completely embolized. The amount of ABSL in high Radkowski stage cases may be influenced by the involvement of intracranial structures, although experience of the resecting surgeon cannot be ignored. Certainly, embolization has proven helpful even in highly aggressive cases, as shown in Case 3 with a tumor size of 85 mm×69 mm×47 mm and a Radkowski stage 2c. Strategic selection of critical tumor feeders from the ICA circulation, such as the meningohypophyseal trunk (Case 4), may also serve in predicting ASBL.
Our case series continue to provide evidence on the safety and efficacy of the BAE technique in tumor embolization of JNA. Furthermore, the concept of balloon-assisted protection to embolize complex, highly vascularized tumors may be applied in other endovascular surgical situations, warranting further research.
CONCLUSIONS
Currently, most interventionists continue to embolize JNA tumors without considering the use of balloon protection of the ICA from the embolic material in the setting of ECA-ICA anastomoses, leading to surgical complications and incomplete embolization. In this study we provide more strength to the argument that the BAE technique is a safe and effective approach to perform successful embolization, eliminating the risk of embolic stroke and continuing to reduce blood loss during surgery.
XML Download